Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Three Drugs Marginally Better Than Two in First-Line Metastatic Colorectal Cancer

January 25th 2016

Patients with metastatic colorectal cancer (mCRC) had marginal yet inconsistent improvement in clinical outcomes when treated with a three-drug chemotherapy regimen plus bevacizumab compared with a doublet-bevacizumab regimen.

Panitumumab Improves Survival in Chemorefractory mCRC

January 25th 2016

Adding panitumumab (Vectibix) to best supportive care reduced the risk of death by 30% for patients with RAS wild-type chemorefractory metastatic colorectal cancer.

Neoadjuvant Carboplatin/Paclitaxel Showing Potential in Esophageal Cancer

January 25th 2016

Neoadjuvant treatment with carboplatin and paclitaxel-based chemotherapy produced a 27.9% pathologic complete response rate in patients with resectable esophageal cancer, according to results of the NEOSCOPE trial.

Avelumab Clinically Active in Advanced Gastric/GEJ Cancer

January 23rd 2016

The investigational antiâ€“PD-L1 antibody avelumab demonstrated clinical activity as a second-line and maintenance therapy for patients with unresectable gastric or gastroesophageal junction cancer.

Dr. Shahda on BBI-608 With Gemcitabine and Nab-Paclitaxel in Patients with mPDAC

January 23rd 2016

Safi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study examining the cancer stem cell pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Hong on High-Dose Hypofractionated Proton Beam Therapy for Liver Cancer

January 23rd 2016

Theodore S. Hong, MD, director, Gastrointestinal Service, Department of Radiation Oncology, discusses high-dose hypofractionated proton beam therapy for unresectable primary liver cancers.

Neoadjuvant Sorafenib Shows Significant Activity in HCC

January 23rd 2016

Nearly a quarter of patients with resectable hepatocellular carcinoma experienced major tumor necrosis of greater than or equal to 50% following preoperative treatment with sorafenib.

Nivolumab Shows Clinical Activity in Gastric Cancer

January 22nd 2016

The PD-1 inhibitor nivolumab (Opdivo) had an overall response rate of 14% with an acceptable safety profile in patients with gastric or gastroesophageal junction cancer.

Dr. Abou-Alfa on Sorafenib Plus Doxorubicin in Patients With HCC

January 22nd 2016

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CALGB 80802 study, which examined sorafenib versus sorafenib plus doxorubicin in patients with advanced hepatocellular carcinoma in the first-line setting.

Dr. Bekaii-Saab on Sequencing Regorafenib and TAS-102 in CRC

January 22nd 2016

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses sequencing regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

Nivolumab Active in Heavily Pretreated Esophageal Cancer

January 22nd 2016

The immune checkpoint inhibitor nivolumab demonstrated activity in patients with previously treated esophageal cancer.

Liposomal Irinotecan OS Advantage Maintained in Updated Pancreatic Cancer Data

January 21st 2016

Adding liposomal irinotecan to 5-fluorouracil and leucovorin reduced the risk of death by 25% for patients with metastatic pancreatic cancer following progression on a gemcitabine-based regimen.

Holly Prigerson on Chemotherapy Regimens for Patients With Advanced Gastric Cancer

January 21st 2016

Holly G. Prigerson, PhD, professor of Sociology in Medicine, Irving Sherwood Wright Professor in Geriatrics, Joan and Sanford I. Weill Department of Medicine, director, Center for Research on End of Life Care, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses chemotherapy regimens for patients with advanced gastric cancer.

Dr. Chak on Challenges With Screening For Esophageal Cancer

January 21st 2016

Amitabh Chak, MD, professor of Medicine, Gastroenterology, Case Western Reserve University School of Medicine, discusses challenges with screening patients for Barrett's esophagus and esophageal cancer.

Dr. Krampitz on Therapeutic Targets in pNETs

January 21st 2016

Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors.

Novel Approaches Explored in HER2-Positive Gastric Cancer

January 18th 2016

Yelena Y. Janjigian, MD, discusses possible causes of the negative LOGiC trial results, HER2 as a driver in esophagogastric cancer, and what the future holds for lapatinib.

Expert Discusses Emerging Treatments, Immunotherapy Potential in pNETs

January 14th 2016

Pamela L. Kunz, MD, discusses several recent studies that shown promise for the treatment of pancreatic neuroendocrine tumors (NETs), as well as other ongoing trials investigating the potential of immunotherapies in NETs.

NYU Expert Examines Emerging Agents in Colorectal Cancer

December 31st 2015

Jennifer Wu, MD, sheds light on TAS-102, as well as some emerging agents likely to play a role in the treatment of patients with colorectal cancer.

Expert Discusses Future of Treatment in CRC

December 30th 2015

John L. Marshall, MD, discusses treatment advancements and other ongoing developments in colorectal cancer.

Dr. Wiesner on Importance of Genetic Testing for CRC

December 28th 2015

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the importance of genetic testing for colorectal cancer.